Sangamo Therapeutics

12/17/2018

This morning Sangamo announced the treatment of the first patient in our phase 1/2 clinical trial of our in vivo genome editing therapy for hemophilia B. https://goo.gl/VQu4uU

12/13/2018

Sangamo Europe at the Antigen-Specific Immune Tolerance Conference in London.

12/03/2018

This morning we are pleased to announce the completion of the acquisition of TxCell. https://goo.gl/qNovXN

11/01/2018

This morning we announced that our third quarter earnings call will take place on Thursday, November 8 at 5 pm ET. Click here for webcast details: https://goo.gl/oBKS5D

10/01/2018

This morning we are pleased to announce the completion of the acquisition of TxCell. Read more here: https://goo.gl/JqVZCi

09/28/2018

We are excited to share our new and improved corporate website!

Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation. Meet the leaders and learn more about Sangamo's latest developments.

09/24/2018

Earlier today we announced our participation at upcoming industry and investor conferences. Click here to read where we will be presenting:

Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences News provided by Sangamo Therapeutics, Inc. 16:15 ET Share this article RICHMOND, Calif., Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq :SGMO ) announced today that management will particip...

09/05/2018

A recording of today's conference call on our 16 week MPS II clinical data can be found through the following link:

09/05/2018

Today we announce our 16 week clinical results, including reductions in glycosaminoglycans in our phase 1/2 trial evaluating SB-913, a zinc finger nuclease genome editing treatment for MPS II (Hunter Syndrome).

SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed,Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks,SB-913 has been generally well...

08/30/2018

Today we announced our upcoming conference call to review SB-913, study data and our participation at upcoming investor conferences.

Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences News provided by Sangamo Therapeutics, Inc. 08:00 ET Share this article RICHMOND, Calif., Aug. 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq : SGMO )....